🚀 LRCX $5.6M Post-Earnings LEAP — Smart Money Targets $315 After Record Beat!

📅 April 23, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just loaded up $5.6 MILLION in LRCX call LEAPs at 13:26 today — the afternoon after Lam Research crushed its FQ3 print with a record $5.84B quarter and guided June revenue to a blowout $6.6B. This isn't a random gamble: it's a conviction bet that the AI-driven etch/deposition supercycle sends LRCX to JPMorgan's fresh $315 price target — 21.6% above where the stock sits right now at $259.10. Translation: big money just decided the post-earnings dip is a buying opportunity, not a warning sign.

---

📊 Company Overview

Lam Research (LRCX) is one of the five dominant companies that supply the machines that build every chip on the planet. Specifically, Lam builds the tools that etch tiny circuit patterns and deposit ultra-thin films — two of the most critical steps in making advanced semiconductors.

• Market Cap: ~$334B — one of the largest semiconductor equipment companies on earth
• Industry: Semiconductor Equipment (Wafer Fabrication Equipment — etch, deposition, clean)
• Core Products: Etch tools (Kiyo, Flex, Sense.i), deposition systems (Vector PECVD, ALTUS), and electrochemical copper plating (SABRE 3D) used in every HBM memory die, 3D NAND stack, and leading-edge logic chip made today
• Why it matters for AI: Every NVIDIA GPU uses stacked HBM memory. Every HBM stack requires Lam's TSV etch tools and SABRE 3D copper plating. There is no AI chip without Lam Research inside it.
• Current Price: $259.10 (April 23, 2026) | YTD: +53.7% per Meyka
• 52-Week Range: $62.56 – $273.50, all-time high $272.41 set April 14, 2026 per MacroTrends

---

💰 The Option Flow Breakdown

📊 What Just Happened

The Tape (April 23, 2026 @ 13:26:14):

🤓 What This Actually Means

This is a long LEAP call — a bullish bet with roughly 9 months of runway. Here's the breakdown:

• 💸 $5.6M dropped: Paid $41.40 per contract × 1,350 size in a single sweep (2,800 total volume vs. just 853 open interest — new positioning is being opened aggressively)
• 🎯 Strike $300: The stock is at $259.10 today. This trade needs LRCX to rally ~16% from the entry price to get into the money by January 15, 2027
• ⏰ Expiration 2027-01-15: About 9 months of time — this is not a short-term punt. It captures the next two Lam earnings reports (July 2026, October 2026), the AMAT peer read-through in May, HBM4 production ramp milestones, and any further WFE guidance raises
• 📊 Volume/OI ratio: 3.28x — the volume is more than triple existing open interest, which strongly signals this is fresh capital coming in, not existing holders rolling or closing
• 🔥 Z-Score 44.75 — EXTREMELY UNUSUAL: For context, a Z-score of 44.75 means this trade is 44+ standard deviations above the average flow in this name. You might see trades this unusual a few times a year in LRCX. Not everyday activity — this is institutional conviction, point blank.

The story here is clean: Earnings just printed a record quarter. The guide raised numbers well above what the Street was modeling. Banks are upgrading targets to $290–$315. And within 24 hours, someone spends $5.6M on a 9-month $300 call. They're telling you exactly where they think this stock is going.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

LRCX has absolutely run this year — up +53.7% YTD coming into today. The stock launched from the low $60s in January and has been in a near-relentless grind higher, touching a new all-time high of $272.41 on April 14 before cooling slightly into the earnings event. Today's print was well received intraday, and the stock is holding in the high $250s as the dust settles.

Key YTD observations:

• 🚀 Parabolic YTD move: LRCX is one of the best-performing large-cap names in the semiconductor equipment space in 2026 — +53.7% rewards were NOT given to passive holders, this was driven by fundamental re-rating
• 📈 Pre-earnings consolidation resolved bullishly: The pullback from the $273 all-time high into the print looked like normal digestion; the record beat + raise confirms this wasn't distribution
• ⚠️ Near all-time highs: The stock sits just 4% below $273.50. Breaking that level opens technical room toward the $280–$300 zone based on Fibonacci projection and analyst targets

Gamma-Based Support & Resistance Analysis

Current Price: $256.30 (GEX snapshot at 14:40 April 23)

The gamma map shows where market makers are heavily positioned — these are the price levels that act like magnets and barriers for near-term price action.

🔵 Support Levels (Put Gamma Below Price):

• $250 — Strongest support at 5.59 total GEX. This is the LINE IN THE SAND — the biggest gamma floor below current price, only 2.5% away. Dealers will buy dips aggressively here to balance their books.
• $245 — Secondary support at 1.69 total GEX; roughly 4.4% below spot.
• $242.50 — Mid-level support at 1.59 total GEX; 5.4% below current price.
• $240 — Deep support at 4.29 total GEX; 6.4% below spot. Notably, this also aligns with the 0.382 Fib retracement from the catalyst research technical chart per TradingView technicals.
• $230 — Extended floor at 2.75 total GEX; 10.3% below current price.
• $220 — Disaster level at 1.69 total GEX; ~14% below price — aligns with major structural support per the catalyst report.

🟠 Resistance Levels (Call Gamma Above Price):

• $260 — Immediate ceiling at 5.41 total GEX — the strongest resistance level, just 1.4% overhead. This is the near-term battle zone. Market makers have heavy exposure here and will sell into any rallies.
• $265 — Next resistance at 3.99 total GEX; 3.4% above spot.
• $270 — Strong resistance at 4.08 total GEX; 5.3% overhead. This zone ($265–$270) converges with the all-time high zone — a key technical test.
• $280 — Extended resistance at 2.62 total GEX; 9.2% above spot. Breaking here would be a decisive breakout signal.

Net GEX Bias: Slightly Bearish (total call GEX 26.94 vs. put GEX 28.80) — meaning near-term dealer positioning is providing slight downward pressure, which fits with the stock's sideways-to-down movement in the days following the all-time high. This is NOT a major structural imbalance — it reflects post-earnings digestion, not a directional collapse signal.

What this means for the $300 call trade: The buyer knows $260, $265, $270 are all resistance layers to work through. They bought a 9-month LEAP specifically because they don't need those levels to break tomorrow — they need the fundamental catalyst stack (AMAT read-through, FQ4 print, HBM4 ramp, potential WFE guidance to $145B+) to push the stock through those walls over time.

Implied Move Analysis

What options pricing is telling us about expected moves:

• 📅 Weekly (April 24 — tomorrow): ±$8.35 (±3.25%) → Range: $248.50 – $265.20 The one-day post-earnings implied move reflects that short-term volatility remains elevated after the print. The market is still processing the guide raise.

• 📅 Monthly OPEX (May 15 — 22 days): ±$28.16 (±10.96%) → Range: $228.69 – $285.01 A nearly 11% expected move by May 15 captures AMAT earnings (May 14) and any post-earnings LRCX analyst note flow. The upper end of $285 is meaningful — that's already approaching Goldman's $290 target.

• 📅 Triple Witch (June 19): Range: $218.55 – $295.15 The upper end at $295 is almost at the JPMorgan $315 target zone, suggesting the options market is embedding that possibility as a real tail scenario.

• 📅 July OPEX (July 17 — captures next LRCX earnings!): Range: $213.48 – $300.22 This is the KEY one for our $300 call trade. The options market itself is pricing the upper implied move to $300.22 by July 17 — which is almost precisely the call strike. The LRCX FQ4 earnings print in late July 2026 is the single biggest catalyst window for this trade.

• 📅 January 2027 OPEX (2027-01-15 — the expiration of this trade): Range: $170.39 – $343.31 By expiration, the market is pricing a ~$86 range on either side. The upper range of $343 implies the $300 strike has meaningful probability of landing in-the-money. This isn't wishful thinking — this is what the options market itself is pricing.

Translation for regular folks: The $300 call buyer is not alone in seeing a path to those levels. The implied move data shows the market's own probability distribution extends well above $300 by the January 2027 expiration. They're paying $41.40 per contract to ride the upper wing of that distribution.

---

🎪 Catalysts

✅ Already Happened — What Just Powered This Trade

FQ3 FY26 Earnings — April 22, 2026 (THE TRIGGER)

Lam just delivered its best quarter ever. Per the official earnings transcript on Motley Fool and Benzinga's complete call coverage:

• 📊 Revenue: $5.84B, +9% QoQ, +24% YoY. The top-line was fractionally below the $5.88B consensus — but the beat story is EPS and the forward guide, not this quarter's revenue.
• 💰 Non-GAAP EPS: $1.47 — a record, and $0.09 above the $1.38 consensus per MarketBeat
• 📦 CSBG Revenue: $2.1B — this is the spares/services/upgrades business, and it just crossed $2B for the first time in history (+25% YoY). This is pure margin, recurring-ish revenue that makes LRCX earnings quality very high.
• 🏭 Gross Margin: 49.9%, operating margin 35.0% — both at the high end of guidance, showing excellent factory discipline per TIKR's earnings summary
• 🧠 Memory systems mix: DRAM hit a record 27% of systems revenue (up from 23%); foundry at 54%; NAND at 12%. The HBM drive is very real and accelerating.

FQ4 Guidance — The Real Bombshell

Per Investing.com's earnings call transcript coverage:

• 🚀 Revenue guidance: $6.6B ± $400M — the midpoint implies ~13% sequential growth. The Street had modeled around $6.1B before tonight. That is a $500M above-consensus guide — not a rounding error.
• 📈 EPS guided to $1.65 ± $0.15 — another record quarter in the making
• 💪 Gross margin target 50.5% — a full 50%+ gross margin quarter would be a first, signaling further product mix improvement from HBM and advanced packaging tooling

WFE Outlook Raised to $140B

Management raised the 2026 global Wafer Fabrication Equipment forecast to ~$140B (from $135B) with an explicit "upward bias," noting Lam's served available market will expand to slightly more than mid-30s percent of that WFE — meaning Lam is growing its share of a growing pie per Insider Monkey's deep dive.

Wall Street Went Bananas

Four banks upgraded/raised targets within 24 hours of the print:

• 🏆 JPMorgan raised PT to $315 from $300, Overweight — that's exactly the strike zone our LEAP buyer is targeting
• 💰 Goldman Sachs raised PT to $290 from $262, Buy — cited "well positioned for outperformance" in deposition, etch, and the NAND upgrade cycle
• 📈 Stifel raised PT to $300 from $280, Buy — WFE exposure argument
• ✅ Cantor Fitzgerald reiterated Overweight on April 23

Average Street PT from these four revisions: ~$301. Our $300 call is consensus on the Street.

---

🔥 Upcoming Catalysts — What Could Drive the Trade Higher

Applied Materials (AMAT) FQ2 FY26 — May 14, 2026 (3 Weeks Away!) 🏭

Per the official Applied Materials investor relations calendar, AMAT reports after the close on May 14. This matters for LRCX because:

• AMAT is the closest peer in WFE — same customers, same capex pools
• AMAT's commentary on GAA logic, advanced packaging revenue, and China exposure will either confirm or challenge the $140B WFE thesis that's underpinning LRCX's post-earnings rally
• A strong AMAT print + guide would be rocket fuel for semi-equipment names — weak AMAT would put near-term pressure on LRCX even with the strong guide already delivered

LRCX FQ4 FY26 Earnings — Late July 2026 🎯

This is THE catalyst for the $300 call trade. Lam just guided to $6.6B revenue and $1.65 EPS. If the June quarter delivers:

• Revenue at or above $6.6B midpoint
• Any additional WFE raise (from $140B toward $143–$145B)
• Advanced packaging revenue trending toward the >50% CY26 growth target
• DRAM/HBM systems mix sustaining record levels

...then analysts will be forced to raise 2026 numbers yet again, and $315+ becomes a near-term reality.

HBM4 Production Ramp — 2H26

SK Hynix, Samsung, and Micron are all competing for NVIDIA's supply contracts for the new 16-Hi HBM4 stacks. Every single HBM4 die needs Lam's Vantex etch and SABRE 3D copper electroplating — there is literally no workaround. As HBM4 production ramps through 2H26, Lam pulls are direct and measurable. Micron's 2026 capex is guided to $13.5B (+23% YoY) with explicit TSV expansion — that money flows to Lam.

NAND $40B Multi-Year Upgrade Cycle

Per StockStory's earnings deep dive, Lam flagged an approximately $40B multi-year NAND upgrade cycle for 200+ layer node conversions, with a portion pulled forward into 2026. 3D NAND channel-hole etch is one of the most critical — and most Lam-specific — process steps in the industry. As NAND makers upgrade nodes, Lam is the primary beneficiary.

SEMICON West — July 2026 (Phoenix)

Lam typically provides updated SAM/share commentary at this industry event. Any upward revision to the mid-30s% SAM share framing would be interpreted as additional upside to the WFE-based revenue math.

---

🎲 Price Targets & Probabilities

Using the gamma levels, implied move data, analyst consensus, and the incoming catalyst stack, here is how the scenarios break down through the 2027-01-15 expiration of this trade:

📈 Bull Case — $315 (20% probability)

Target: $300–$343

How we get there:

• 🚀 FQ4 June quarter delivers $6.6B+ revenue, EPS at $1.65 high end or above, gross margin crosses 51%
• 💡 WFE outlook raised a second time — toward $143–$145B by late July earnings
• 🧠 Advanced packaging revenue tracking to >60% CY26 growth (beats the >50% target)
• 📊 DRAM mix continues rising as HBM4 ramp accelerates — NVIDIA's Rubin GPU is pulling hard
• 🎯 JPMorgan's $315 target gets hit by September/October 2026; rally continues toward December triple witch at $335 implied upper range
• 🌐 China clarity — any export restriction loosening provides a free upside option on $1.99B quarterly revenue base

On the $300 call: At $315 by January 2027, the $300 call is worth ~$15+ intrinsic (ignoring residual time premium). On 1,350 contracts that's ~$2.0M profit on a $5.6M investment — a 36% return. At $330, the intrinsic alone is ~$30, generating ~$4M+ in profits.

The gamma/implied move confirms it: The January 2027 OPEX upper range is $343.31 — the market itself has already priced this as a real possibility.

🎯 Base Case — $270–$285 (55% probability)

Target: Current to Goldman's $290 target

Most likely scenario:

• ✅ FQ4 prints in line with guidance — $6.6B revenue, $1.65 EPS — no major surprise either direction
• 📊 Stock grinds through gamma resistance at $260, $265, $270 over the coming months
• 🏦 AMAT on May 14 delivers a solid print, confirming the WFE thesis without a blowout
• 📈 LRCX consolidates between $255–$280 through summer, builds a base before July earnings
• 🎯 Goldman's $290 target acts as a near-term ceiling — stock approaches but does not decisively clear it before the next earnings catalyst
• 🔄 Advanced packaging revenue tracks toward $50% growth target, confirming thesis without acceleration

On the $300 call: At $275–$285 by January 2027, the $300 call expires out-of-the-money, and the $41.40 paid decays toward zero. The trade loses money in the base case — this is a directional LEAP bet, not a hedge. You need real upside to make it work.

The gamma picture: The $260, $265, $270 resistance walls are real. Slowly working through them is the base-case grind.

📉 Bear Case — $230–$250 (25% probability)

Target: $240–$250 support zone

What could go wrong:

• 😰 China export controls tighten further beyond the guided $600M headwind, pressuring the 34% of revenue that came from China in FQ3 per Insider Monkey
• 📉 Broader semiconductor equipment selloff — AMAT disappoints on May 14 with weak China or advanced packaging commentary
• 💸 Memory capex goes "cautious" — TrendForce has flagged cautious memory capex despite HBM strength; any DRAM price rollover could soften customer spending
• ⚠️ FQ4 execution: a $600M miss vs. guidance (landing at $6B instead of $6.6B) would crater sentiment at a stock trading 20x+ EV/EBITDA per Seeking Alpha's valuation comparison
• 🔨 Break below $250 gamma support triggers technical cascade toward $240–$242 range

Critical support floors from gamma data:

• 🛡️ $250 (5.59 total GEX — strongest support near spot): First line of defense, 2.5% below current price
• 🛡️ $240 (4.29 total GEX): Major structural floor — also matches the 0.382 Fib retracement level per TradingView
• 🛡️ $230 (2.75 total GEX): If both $250 and $240 break, this is the next significant buyer level

On the $300 call in the bear case: At $230–$240 in January 2027, the $300 call is deeply out-of-the-money and worth essentially $0. The $5.6M premium paid is mostly or entirely lost.

---

💡 Trading Ideas

🛡️ Conservative: The "Lock In the Story" Bull Call Spread

Play: Buy the $260 / $290 call spread, January 2027 expiration

Why this works:

• 📊 Defined risk — you know the max loss before you enter
• 🎯 Captures a move to Goldman's $290 target without paying for the full $300+ LEAP premium
• 💸 A $260/$290 spread costs roughly $15–$18 net debit (varies by current IV) vs. $41.40 for the naked $300 call in the news
• 📈 The upper breakeven aligns with the May 15 OPEX upper implied range at $285.01 — you're betting on the same thesis with lower cost
• ⏰ 9 months of time gives the HBM4 ramp, AMAT print, and FQ4 print to all work in your favor

Position sizing: Risk only 2–4% of portfolio maximum. This is a directional bet, not a core holding.

Risk level: Moderate (defined, limited to debit paid) | Skill level: Intermediate | Probability of profit: ~35–45%

⚖️ Balanced: The "Ride With the Whale" Shorter-Term Call

Play: Buy LRCX $270 calls, June 19, 2026 expiration (Triple Witch)

Why this works:

• 🎪 Captures AMAT earnings (May 14) and positions ahead of LRCX FQ4 (late July — this expires before, so you take profits or roll)
• 📊 June 19 Triple Witch implied upper range is $295.15 — the market is already pricing a move to near-$295 as a reasonable scenario by late June
• 💰 The $270 strike is only 4.2% above the resistance zone ($260/$265), meaning a gamma breakout through the wall sends you in-the-money quickly
• 🎯 $270 target aligns with the all-time high zone — once that breaks decisively, there's no technical overhead until $280+
• ⏰ Triple Witch June 19 provides natural exit liquidity

Exit plan: Take profit if LRCX hits $275–$280 before expiration. Roll to July OPEX for the earnings catalyst if the trade is working and IV remains reasonable.

Risk level: Moderate-High (long premium, time decay is real) | Skill level: Intermediate | Probability of profit: ~30–40%

🚀 Aggressive: Mirror the Whale — January 2027 $300 Calls

Play: Scale into the same trade the institutional buyer made at 13:26 today

Structure: Buy LRCX $300 calls, 2027-01-15 expiration, at market

Why this could work:

• 🐋 You're following a $5.6M conviction bet placed by an institutional player who just watched the earnings transcript and decided the setup is compelling enough to spend $5.6M in one single block
• 📈 Z-score of 44.75 — this is one of the most unusual trades LRCX has seen this year. A handful of times annually you see trades this outsized. This is the kind of unusual flow that worth paying attention to.
• 🎯 The January 2027 implied move upper range is $343.31 — the options market itself agrees that $300+ is within the cone of possibility
• 💰 If the $315 JPM target is hit, the $300 call is worth $15+ intrinsic. At $330 it's worth $30+. This is a high-reward scenario if the fundamental thesis plays out.
• 🏦 JPMorgan's $315 target is now buy-side consensus — you're trading toward the Street's own price objective

The brutal math you need to know:

• ❗ At $41.40 per contract, you need LRCX above $341.40 at expiration just to break even (strike $300 + $41.40 premium)
• 💡 But you don't hold to expiration. If LRCX runs to $290–$300 by October, the $300 call may have $15–$20 of intrinsic + time value — you take profits well before the January 15 expiry date
• 📊 This trade has probably a 20–25% probability of profitable outcome by expiration but can generate 100%+ returns if the bull case plays out
• 💸 Size this to your max you are comfortable losing 100% of. This is aggressive.

CRITICAL WARNING: This is an out-of-the-money LEAP. If LRCX does not rally to $300+ and you hold to expiration, you lose the entire $41.40 per contract. Options trading involves substantial risk. This is the aggressive tier for a reason.

Risk level: HIGH (can lose 100% of premium) | Skill level: Advanced | Probability of profit at expiry: ~20–25%

---

⚠️ Risk Factors

Don't ignore these before you decide:

• 🇨🇳 China is a $1.99B quarterly exposure and it's getting squeezed: China represented 34% of LRCX's FQ3 revenue — that is massive. Management is already guiding a $600M revenue headwind in 2026 from newly tightened export restrictions on legacy equipment. The Congressional Research Service R48642 outlines how ongoing U.S. export policy continues to evolve — one Commerce Department announcement can swing LRCX $1–2B in annual revenue without warning. This is the single largest near-term risk, full stop.

• 💰 Insiders are selling, nobody is buying: Per Quiver Quantitative, there have been 13 insider transactions over the past six months — 13 sells, 0 buys. CEO Timothy Archer alone sold 163,300 shares for ~$26.76M. Aggregate insider sales in the past three months: ~$29.7M. This is normal behavior after a 54% YTD run (execs need to diversify their equity-heavy comp), but it is worth knowing as context. Smart money on the inside is not adding, they're trimming.

• 📊 Valuation is already stretched: LRCX trades at ~20.4x EV/EBITDA versus AMAT at 13.8x and TEL at 17.7x per Seeking Alpha's equipment comparison. The premium reflects the market's expectation that Lam will deliver beat-and-raise quarters through 2027. That means there's limited margin for error — miss a quarter, and the multiple compresses fast.

• 📈 RSI is elevated, stock already up 54% YTD: Per TradingView's technical readings, RSI is flagged as elevated. The stock has run hard into the earnings print. Near-term consolidation in the $250–$270 range is the base case, not an immediate moonshot. LEAP buyers can handle this — 9-month timeframes absorb consolidation. But if you're buying shorter-dated options looking for a quick post-earnings pop, you may be disappointed.

• 🏭 Memory capex is cautious despite HBM strength: TrendForce explicitly notes memory makers maintaining "cautious capex" in 2026 even as HBM3E pricing rises. Samsung and SK Hynix are limiting new NAND investment to focus on HBM/DRAM. If DRAM or HBM pricing rolls over in 2H26, the 39% memory systems mix that LRCX just reported could become a headwind, not a tailwind.

• ⚡ CXMT is NOT coming to rescue China revenue short-term: Per Digitimes, CXMT's HBM3 mass-production is slipping to beyond 2026. So even if China export controls stayed flat, there's no incremental China memory capex wave to absorb. The China revenue trajectory is down, not up, absent a policy reversal.

• 🎢 A $41.40 per contract option needs significant upside to profit: This is the math reality for the aggressive play. The stock needs to reach $341+ at expiration for break-even on the $300 call. Institutional buyers of LEAPs typically exit well before expiration when the position appreciates — but retail traders need to understand the full risk of holding to expiry. Options are asymmetric instruments: you can lose 100% of what you put in.

---

🎯 The Bottom Line

Here's the deal: Someone just bet $5.6 million that the AI-driven etch/deposition supercycle lifts LRCX to the $300+ zone before January 15, 2027. They did it the afternoon after the best quarterly print in Lam's history, with four banks upgrading in the same 24-hour window. This is not confused — this is a very deliberate positioning decision.

What the $300 call trade tells us:

• 🐋 A large institutional player looked at the $6.6B FQ4 guide, the $140B WFE outlook with "upward bias," the HBM4 ramp, the NAND $40B upgrade cycle, JPMorgan's $315 target — and decided this thesis plays out over 9 months
• ⏰ The 2027-01-15 expiration is not an accident — it captures TWO more Lam earnings reports (July and October 2026), the full HBM4 production ramp, and the NAND upgrade pull-forward
• 🎯 The $300 strike is literally consensus: average of JPM ($315), Goldman ($290), and Stifel ($300) gets you to ~$301. The buyer is paying for a move to where four major banks already say the stock should go.

If you already own LRCX stock:

• ✅ Today's action confirms the fundamental thesis remains fully intact — record quarter, record guide, WFE raised. Hold your position.
• 📊 Use the $250 gamma support level as your mental stop for deciding whether the thesis has broken (it hasn't until that level cracks meaningfully)
• 🎯 If the stock continues to consolidate near $255–$265, that's the healthy base-building phase before the July earnings catalyst gives the next leg up

If you're watching from the sidelines:

• 📅 May 14 is AMAT's print — watch that for sector confirmation before committing to LRCX-specific options
• 📅 Late July 2026 is LRCX FQ4 print — the biggest single catalyst window for this $300 call trade
• 🎯 If LRCX pulls back to the $250–$255 gamma support zone (a 2–3% dip from current), that is a more favorable risk/reward entry point for any of the three trading ideas above
• 📊 The advanced packaging >50% growth target, HBM4 ramp, and NAND upgrade cycle are multi-year structural tailwinds — the story is not going away

If you're leaning bearish:

• 🇨🇳 The China $600M headwind is the cleanest bear argument — watch Commerce Department announcements closely
• 📉 Key levels to watch: break below $250 (5.59 GEX support) is the first warning; break below $240 (4.29 GEX) is the escalation signal
• ⚠️ Post-earnings momentum is still fresh — fighting the tape the day after a record beat + $6.6B guide is a difficult short. Wait for a natural opportunity, not an emotional counter-trend.

Mark your calendar — Key Dates:

• 📅 May 14, 2026 — Applied Materials FQ2 FY26 earnings (peer read-through, sector signal)
• 📅 May 15, 2026 — Monthly OPEX (implied range: $228.69 – $285.01)
• 📅 June 19, 2026 — Triple Witch (implied range: $218.55 – $295.15)
• 📅 Late July 2026 — LRCX FQ4 FY26 earnings (THE main catalyst; exact date TBA)
• 📅 July 2026 — SEMICON West industry conference, Phoenix
• 📅 2027-01-15 — Expiration of the $5.6M LRCX $300 call trade

Final verdict: Lam Research just had its best quarter ever and guided to an even bigger one coming. The AI picks-and-shovels trade is real — every HBM die, every 3D NAND stack, every GAA logic chip goes through Lam equipment. The $5.6M LEAP buy is a measured, forward-looking institutional conviction trade, not a panic buy. The risk/reward favors bulls through the July earnings catalyst, with $250 as the near-term line in the sand on the downside and JPM's $315 as the credible bull target 9 months out.

The etch and deposition supercycle is not over. It is accelerating. Buckle up. 🚀

---

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational and informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. The unusual Z-score reflects this specific trade's size relative to recent LRCX history and does not imply the trade will be profitable or that you should replicate it. Out-of-the-money LEAP options frequently expire worthless — a 100% loss of premium paid is a real and common outcome. Past performance does not guarantee future results. The $600M China headwind, memory capex cyclicality, and insider selling are real risks that must be weighed against the bullish case. Always do your own research and consider consulting a licensed financial advisor before trading options.

---

About Lam Research: Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor wafer processing equipment used in the fabrication of integrated circuits, with ~$334B market cap and dominant positions in conductor/dielectric etch and electrochemical deposition — the most critical process steps in HBM, 3D NAND, and leading-edge logic semiconductor manufacturing.